About the Hemostats and Tissue Sealants Market
Blood clotting or coagulation, is an important process that eliminates excessive bleeding when a blood vessel is damaged. Platelets and proteins work together to stop the bleeding by forming a clot over the injury. Blood clottage is one of the mechanisms that reduce the loss of blood from damaged blood vessels.Hemostats and tissue sealants are used post-surgery or traumatic injury to bind or hold external tissue (skin) as well as internal tissue (blood vessels). Some key types of hemostats and tissue sealants include fibrin sealants, collagen-based compounds, synthetic agents, and tissue adhesive glues such as hydrogels and glutaraldehyde glues. Fibrin sealants have a wide range of medical applications.
Technavio’s analysts forecast the global hemostats and tissue sealants market to grow at a CAGR of 8.72% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global hemostats and tissue sealants market for 2016-2020. To calculate the market size, Technavio uses revenue generated from the following products:
Technavio Announces the Publication of its Research Report – Global Hemostats and Tissue Sealants Market 2016-2020
Technavio recognizes the following companies as the key players in the global hemostats and tissue sealants market: Advanced Medical Solutions group, Baxter International, C. R. Bard, Cryolife, CSL Behring, Integra LifeSciences, and Johnson & Johnson (Ethicon).
Other Prominent Vendors in the market are: B. Braun, Cardinal Health, Cohera Medical, Haemacure, HyperBranch Medical Technology, NeoMend, Smith & Nephew, Teijin Pharma, Tissuemed, Vascular Solutions, Vivostat, and Z-Medica.
Commenting on the report, an analyst from Technavio’s team said: “One trend that will boost market growth is the approval of fibrin sealants as broad level hemostats. Fibrin sealants aid in the rapid formation of a stable clot. They can be applied to small blood vessels and to areas that cannot be addressed with conventional sutures. Also, fibrin sealants reduce the amount of blood loss during surgical procedures and lower the risk of postoperative infection or inflammation. Moreover, fibrin sealants are conveniently absorbed by the body during the wound healing process. Fibrin sealants are particularly useful in MI surgical procedures, especially in treating patients with clotting disorders. Currently, fibrin sealants are approved by the FDA as broad label hemostats for surgical procedures.”
According to the report, a key growth driver is the focus on patient safety and quicker recovery. Surgical wounds are a source of concern for healthcare practitioners, patients, and healthcare organizations, as they can lead to sepsis, pain, and also psychological problems. For instance, according to the CDC, each year 30 million patients in the US are affected by surgical site infections, and the number is increasing at the rate of 2%-5% year-over-year.
Further, the report states that one challenge that could restrict market growth is the paucity of ready-to-use products. In general, most of the products have formulations and are stored separately. Medical professionals need to load the formulations into an applicator device that enables mixing before application on the target surface. This increases the overall time needed to perform the procedure.
Advanced Medical Solutions group, Baxter International, C. R. Bard, Cryolife, CSL Behring, Integra LifeSciences, Johnson & Johnson (Ethicon), B. Braun, Cardinal Health, Cohera Medical, Haemacure, HyperBranch Medical Technology, NeoMend, Smith & Nephew, Teijin Pharma, Tissuemed, Vascular Solutions, Vivostat, Z-Medica.